At a glance
ClinicalIndex Comparison RecordN/ACompleted· 131 enrolled
Drug / intervention
Instanyl (Intranasal Fentanyl)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Non-interventional/Observational Patient Cohort Study on the Efficacy of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients.
In Brief
An observational study evaluating Instanyl (Intranasal Fentanyl) for Breakthrough Pain and Cancer. Completed, enrolled 131 participants across 168 sites.
Detailed Summary
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks. The fentanyl spray was applied into the nose by a metered-spray device. The study was to provide further data on pharmacoeconomic efficiency of intranasal fentanyl spray.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreakthrough Pain, Cancer
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedOct 2009
Primary CompletionSep 2010
Study CompletionNov 2010
TodayJul 2026
First PostedOct 14, 2009
Enrollment StartSep 1, 2009
Primary CompletionSep 1, 2010
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.7 years ago
Interventions
Instanyl (Intranasal Fentanyl)drug
This was an observational study. Therefore, the physician decided about dosage according to individual needs.